10/28/2009 | PP | New Issue: SuperGen completes $3 million placement of shares with GlaxoSmithKline
|
1/27/2009 | SS | Biotechnology Value Fund cuts stake to 10.72% in SuperGen
|
1/21/2009 | CVIG | SuperGen files $100 million shelf
|
11/9/2006 | BT | SuperGen reports record cash balance of $72.97 million
|
7/6/2006 | BT | SuperGen announces Dacogen licensing
|
6/21/2006 | BT | Mayne to acquire North American rights to SuperGen's Nipent and SurfaceSafe for $34 million
|
6/2/2006 | BT | SuperGen receives Nipent patent
|
5/26/2006 | BT | SuperGen earns $20 million Dacogen injection milestone
|
5/25/2006 | BT | SuperGen to use Dacogen income as 'financial engine' to develop new clinical candidates
|
5/3/2006 | BT | FDA approves SuperGen, MGI Pharma's Dacogen for injection to treat patients with myelodysplastic syndromes
|
5/3/2006 | BT | Market Commentary: MGI, SuperGen get nod from FDA for Dacogen; Impax stock climbs on FDA OK of generic Colestid
|
4/26/2006 | BT | SuperGen interim results of Orathecin trial show six-month median survival rate in pancreatic cancer
|
3/14/2006 | BT | SuperGen: pentostatin, cyclophosphamide, rituximab together shown to fight leukemia
|
1/20/2006 | BT | Market Commentary: DOR BioPharma stock jumps 15.6% on orBec news, equity line; Shire, Impax settle patent suit
|
1/20/2006 | BT | SuperGen withdraws European marketing application for Orathecin
|
12/15/2005 | BT | MGI, SuperGen answer FDA questions on Dacogen
|
12/12/2005 | BT | MGI Pharma, SuperGen data show Dacogen may help MDS, AML, CML patients
|
12/9/2005 | BT | SuperGen: studies show Nipent works as well as other chemotherapeutics with less toxicity
|
10/26/2005 | BT | MGI Pharma, SuperGen: Dacogen injection under review in U.S., Europe
|
4/4/2005 | CV | Supergen files $100 million shelf
|